OSD Contract Manufacturing Estimated $54.7 Billion By 2030

According to a market analysis, the global oral solid dosage (OSD) contract manufacturing market is forecast to grow $54.7 billion in value by 2030, growing at a compound annual growth rate (CAGR) of 6%.

Oral solids are the most popular drug delivery technique utilised globally, according to research, since they are highly economical and have simple manufacturing processes. Slow-release versions were a popular choice for manufacturers since they reduce the typical dosage regularity for patients who only need to take these drugs, say, once a week. Additionally, this lessens any unfavourable impacts.

Tablets were anticipated to be the most common OSD in 2021 due to their simplicity in terms of production, distribution, and mobility for the end user. The survey claims that the industry is expanding, especially for bilayer tablets.

Large contract manufacturing organisations (CMOs), which made significant R&D investments as well as contract development and manufacturing organisations, are said to have enhanced market value. Large CMOs generated the highest share of income in 2021 because pharmaceutical companies chose to outsource the work to these organisations even in the early stages of drug manufacture.

Between 2015 and 2020 (1,642 to 2,911), clinical-stage cancer programmes increased dramatically, resulting in a quarter of the drugs now in development being extremely potent. Many pharmaceutical businesses find it challenging to alter their installed capacity due to the growing need for small-scale and enclosed manufacturing techniques needed to create these medicines.

Due to a severe interruption in the raw material supply chain and labour shortages caused by the COVID-19 epidemic, the healthcare sector’s revenue fell in 2020.

This, however, illustrated to industry leaders the value of R&D for drugs intended to treat viral infections, paving the way for this market segment to expand in the years that followed. Two small-molecule oral solids with demonstrated efficacy in treating COVID-19 patients, azithromycin and hydroxychloroquine, have been essential in restarting the market. Since then, many companies have focused on creating and manufacturing OSD drugs thanks to contracts with CMOs. As a result, increased cooperation, adaptability, and flexibility have been significant factors impacting the solid-dosage manufacturing industry.

Asia-Pacific dominated the global market as a whole in 2021, and it is anticipated that it would hold this position going forward with the highest CAGR. By competing in a market where prices are incredibly low, China and India have contributed to the dominance of the OSD CMO sector.